RedHill Biopharma (RDHL) Stock: Gaining On Orphan Drug Designation


RedHill Biopharma Ltd – ADR – (NASDAQ: RDHL)

RedHill Biopharma is having an incredibly strong time in the pre-market trading hours today, and for good reason. The company announced that it has received Orphan Drug Designation. As a result, investor excitement ensued, leading to gains in the value of the stock and prompting our partners at Trade Ideas to alert us of the upward movement. At the moment (8:10), RDHL is trading at $10.00 per share after a gain of 4.60% thus far today.

RDHL Receives Orphan Drug Designation

As mentioned above, RedHill Biopharma is having an incredibly strong morning this morning after announcing that it has received Orphan Drug Designation from the United States Food and Drug Administration. The Orphan Drug Designation has been rewarded for the company’s clinical-stage treatment known as YELIVA(R). YELIVA is designed as a treatment for Cholangiocarcinoma.

Don’t waste your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on RDHL. In particular, we’ll be watching for any news associated with the company’s continued work on YELIVA. Considering the positive news coming out today and recent positive results surrounding the treatment, it is looking more and more promising every day.

What Do You Think?

Where do you think RDHL is headed moving forward? Join the discussion in the comments below or on StockTwits!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required

[Image Courtesy of Wikimedia]

Previous articlePanera Bread (PNRA) Stock: Skyrocketing On Sale Exploration
Next articleGigPeak (GIG) Stock: Halted With News Pending
Hey, Im Joshua, the founder of CNA Finance. I enjoy following the trends in the market and finding the catalysts that are making the moves. If you want to get in contact with me, leave a comment below or email me at Please keep in mind that I am not an investment advisor and nor is CNA Finance. This is a news and information gathering outlet. We may work directly with some of the companies that we write about. If we have a business relationship with an issuer, we will mention that in the articles. We also have various affiliate relationships with advertisers and may be paid if you sign up for a service that you were referred to through our website.


Please enter your comment!
Please enter your name here